No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 63.8x · 10Y median 18.7x · 91st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:47:37.336Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Nurix Therapeutics, Inc. (NRIX) stock was $22.60 as of Oct 6, 2026, 4:00 PM EDT, down 1.22% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +142.9% · 3-year avg +49.3%/yr · 5-year avg -5.5%/yr
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Biotechnology · Brisbane, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-11-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Oct 8, 2026
2 days away
EPS Estimate
-0.60
Revenue Est.
$24.35M
Last Quarter Results
EPS
$-0.81
vs Estimate
$-0.72
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NRIX | $2.35B | $22.60 | -1.22% | +142.89% | -5.51% | N/A | N/A |
| 2UFPT | $2.34B | $302.87 | -1.45% | +57.09% | +37.11% | +27.76% | vs NRIX |
| 3ADMA | $2.36B | $10.18 | +0.69% | -30.91% | +54.74% | +3.85% | vs NRIX |
| 4IRON | $2.37B | $61.65 | -2.65% | -6.54% | +10.70% | N/A | vs NRIX |
| 5CLOV | $2.38B | $4.60 | -1.71% | +80.19% | -8.36% | N/A | vs NRIX |
| 6LQDA | $2.30B | $25.91 | -6.26% | +23.11% | +59.01% | N/A | vs NRIX |
forward FY estimate
N/A
$9.04M
vs Estimate
$15.29M
Consensus Rating
Based on 14 analysts
Average Price Target
$33.93
+50.1% upside
Low
$25.00
Current
$22.60
High
$45.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Aug 2026 | $-0.80 | $-0.60 | $-0.29 | 4 |
| Quarter ending Nov 2026 | $-0.13 | $-0.09 | $-0.03 | 4 |
| Quarter ending Feb 2027 | $-1.73 | $-0.53 | $0.08 | 2 |
| Quarter ending May 2027 | $-1.80 | $-0.55 | $0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.15 | $-2.70 | $-2.02 | 4 |
| FY 2027 | $-3.05 | $-1.97 | $-0.75 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Aug 2026 | $2.45M | $24.35M | $124.10M | 4 |
| Quarter ending Nov 2026 | $13.77M | $27.88M | $57.23M | 4 |
| Quarter ending Feb 2027 | $1.84M | $15.10M | $41.48M | 3 |
| Quarter ending May 2027 | $1.98M | $16.30M | $44.77M | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $16.77M | $68.45M | $274.30M | 4 |
| FY 2027 | $66.58M | $114.53M | $145.81M | 4 |
